Fujian Shengdi Pharmaceutical Co., Ltd.

Pharma

Fuzhou, Fujian, China

A Chinese pharmaceutical company engaged in drug research, development, and commercialization.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 31

Phase 22

Phase 13

By Therapeutic Area

top 3

Metabolic & Endocrine

229%

Cardiovascular

229%

Respiratory

114%

R&D Momentum

74/100

Pipeline Velocity

48/100

Trial Completion Rate

100/100

Pipeline Concentration

27/100

Pipeline Freshness

88/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 5, 2026

Active, not recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Oct 23, 2026

Completed

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Earlier

Oct 21, 2026TrialA Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.

Oct 10, 2026TrialA Multi-center, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

Sep 29, 2026TrialA Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes

Sep 29, 2026TrialA Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of HRS9531 Injection in Chinese Adolescents With Obesity

Sep 26, 2026TrialA Randomized, Double-blind, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a Single Oral Dose of HRS-4139 in Healthy Participants

Sep 26, 2026TrialSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets as a Single Dose in Healthy Participants and Multiple Doses in Obese Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study

4 more events

Sep 23, 2026TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-2162 Injection in Healthy Subjects

Sep 17, 2026TrialA Multicentre, Randomised, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Injectable HRS-9057 in Patients With Heart Failure-induced Fluid Retention

Sep 17, 2026TrialAn Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

Sep 11, 2026TrialA Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants